Ballentine Partners »

Adaptimmune Therapeutics shares owned by Ballentine Partners

Quarter-by-quarter ownership of Adaptimmune Therapeutics (ADAP) shares owned by Ballentine Partners from 13F filings

Historical chart of Ballentine Partners investment in Adaptimmune Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Adaptimmune Therapeutics held by Ballentine Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Adaptimmune Therapeutics by Ballentine Partners

Quarter filed Position value Share count Share price at filing
2024-03-31 $23k 15k 1.58

More positions owned by Ballentine Partners

Vanguard Index Fds Total Stk Mkt (VTI)
Ishares Tr Core Msci Eafe (IEFA)
Ishares Tr Core S&p Ttl Stk (ITOT)
Ishares Core Msci Emkt (IEMG)
Vanguard Tax-managed Fds Van Ftse Dev Mkt (VEA)
Ishares Tr Core S&p500 Etf (IVV)
Vanguard Intl Equity Index F Ftse Emr Mkt Etf (VWO)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Vanguard Index Fds Real Estate Etf (VNQ)
Vanguard Index Fds Large Cap Etf (VV)
Microsoft Corporation (MSFT)
Ishares Tr Rus 1000 Etf (IWB)
Schwab Strategic Tr Us Brd Mkt Etf (SCHB)
Apple (AAPL)
Ishares Tr Core S&p Mcp Etf (IJH)

View all positions for Ballentine Partners

Top funds holding Adaptimmune Therapeutics

NEA Management Company
Baillie Gifford & Co
Long Focus Capital Management
Baker Bros. Advisors
Partner Fund Management
Bank of America Corporation
Tang Capital Management
Citadel Advisors
Syncona Portfolio
Jpmorgan Chase & Co
Redmile Group
GSA Capital Partners
Acuitas Investments
Millennium Management
DAFNA Capital Management

View all funds holding Adaptimmune Therapeutics